Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
The Oncologist|June 23, 2019
Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with CancerElad Neeman, Gillian Gresham, Navasard Ovasapians, et al.
The Journal of Urology|August 18, 2004
Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scansOleg Shvarts, John S Lam, Hyung L Kim, et al.
Case Reports in Urology|March 26, 2019
Brain Complete Response to Cabozantinib prior to Radiation Therapy in Metastatic Renal Cell CarcinomaAn Uche, Chad Sila, Tad Tanoura, et al.
Critical Reviews in Oncology/Hematology|August 14, 2010
Sequential use of targeted agents in the treatment of renal cell carcinomaThomas E Hutson, Ronald M Bukowski, C Lance Cowey, et al.
The Journal of Urology|February 16, 2005
p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinomaOleg Shvarts, David Seligson, John Lam, et al.
Frontiers in Pharmacology|April 6, 2026
DZ-1-artesunate conjugate induces mitochondria-mediated, reactive oxygen species-dependent apoptosis in colorectal cancer tumoroidsBadrinath Narayanasamy, Yi Zhang, Alexandra Gangi, et al.
Molecular Cancer Therapeutics|August 8, 2006
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis modelYusheng Jin, Kenneth K Iwata, Arie Belldegrun, et al.
Oncotarget|March 24, 2018
Reprogrammed lipid metabolism in bladder cancer with cisplatin resistanceMin Young Lee, Austin Yeon, Muhammad Shahid, et al.
The Urologic Clinics of North America|September 5, 2003
Current staging of renal cell carcinomaBradley C Leibovich, Allan J Pantuck, Matthew H T Bui, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptorLinda Garland, Barbara Gitlitz, Scot Ebbinghaus, et al.
Pageof 6